Compare RGP & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGP | MSLE |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 146.9M |
| IPO Year | 2000 | N/A |
| Metric | RGP | MSLE |
|---|---|---|
| Price | $4.71 | $5.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 313.6K | 26.6K |
| Earning Date | 04-08-2026 | N/A |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $5.50 |
| 52 Week High | $6.07 | $13.39 |
| Indicator | RGP | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 39.16 |
| Support Level | $4.21 | $5.50 |
| Resistance Level | $4.82 | $8.59 |
| Average True Range (ATR) | 0.22 | 0.45 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 89.92 | 16.30 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.